BioCryst Pharmaceuticals
BCRX
117 hedge funds and large institutions have $568M invested in BioCryst Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 12 closing their positions.
454% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $2.67M
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
54% more capital invested
Capital invested by funds: $370M → $568M (+$198M)
15% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 34
5.05% more ownership
Funds ownership: 79.16% → 84.22% (+5.1%)
4% more funds holding
Funds holding: 112 → 117 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$41.8M |
| 2 |
Millennium Management
New York
|
+$18.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$7.5M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$5.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$8.42M |
| 2 |
RI
RTW Investments
New York
|
-$4.32M |
| 3 |
D.E. Shaw & Co
New York
|
-$3.68M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.16M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.04M |
BCRX Hedge Fund Activity: Q1 2017 in Review
117 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2017, worth a combined $568M — up 54% from $370M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BCRX positions and 12 closed out — a net gain of 11 holders — while 39 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $41.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $8.42M sold.
- 117 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2017, up from 112 in Q4 2016.
- Funds reported $568M of BioCryst Pharmaceuticals stock for Q1 2017, up 54% quarter-over-quarter.
- 23 funds opened new BioCryst Pharmaceuticals positions in Q1 2017 and 12 closed out, a net change of +11 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $41.8M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2017 was Perceptive Advisors, an estimated $8.42M sold.
Based on aggregated 13F filings for Q1 2017.